American Journal of Hematology
Nov 10, 2025, 10:37
Should Transferrin Saturation Guide HFE-Hemochromatosis Therapy?
American Journal of Hematology shared on X:
“In HFE-hemochromatosis, transferrin saturation above ~75% suggests harmful non-transferrin-bound iron levels. Due to assay limits for NTBI, monitoring TSAT levels during maintenance therapy may help and should guide care until accurate NTBI tests exist.”
Title: Should Serum Transferrin Saturation Be Included as a Therapeutic Target in Addition to Serum Ferritin in Treating HFE-Hemochromatosis?
Authors: Nils Thorm Milman, Christina Ellervik
Read the full article here.
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 11:29Emma Lefrancais: Uncovering A Key Role for The IL-33/ST2 Axis in Platelet Biology with Lucie Gelon
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC